Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 03 04:00PM ET
2.63
Dollar change
-0.33
Percentage change
-11.15
%
IndexRUT P/E- EPS (ttm)-1.65 Insider Own13.99% Shs Outstand113.88M Perf Week8.68%
Market Cap299.54M Forward P/E- EPS next Y-1.67 Insider Trans-0.00% Shs Float97.96M Perf Month8.23%
Income-178.23M PEG- EPS next Q-0.44 Inst Own89.41% Short Float10.61% Perf Quarter-25.28%
Sales13.45M P/S22.27 EPS this Y0.38% Inst Trans-3.84% Short Ratio4.97 Perf Half Y-28.14%
Book/sh3.18 P/B0.83 EPS next Y-2.26% ROA-34.32% Short Interest10.39M Perf Year-0.75%
Cash/sh2.61 P/C1.01 EPS next 5Y- ROE-46.59% 52W Range1.96 - 8.83 Perf YTD-29.68%
Dividend Est.- P/FCF- EPS past 5Y-6.65% ROI-39.22% 52W High-70.22% Beta1.93
Dividend TTM- Quick Ratio8.29 Sales past 5Y87.14% Gross Margin-41.55% 52W Low34.18% ATR (14)0.38
Dividend Ex-Date- Current Ratio8.29 EPS Y/Y TTM6.37% Oper. Margin-1462.06% RSI (14)49.60 Volatility19.72% 15.79%
Employees181 Debt/Eq0.27 Sales Y/Y TTM-87.34% Profit Margin-1325.43% Recom2.53 Target Price6.33
Option/ShortYes / Yes LT Debt/Eq0.25 EPS Q/Q11.67% Payout- Rel Volume1.66 Prev Close2.96
Sales Surprise147.44% EPS Surprise3.96% Sales Q/Q58.13% EarningsNov 12 AMC Avg Volume2.09M Price2.63
SMA205.81% SMA50-7.05% SMA200-38.35% Trades Volume3,472,397 Change-11.15%
Date Action Analyst Rating Change Price Target Change
Nov-18-24Upgrade BofA Securities Underperform → Neutral
Jun-17-24Upgrade Piper Sandler Neutral → Overweight $4 → $6
Mar-27-23Resumed Wells Fargo Equal Weight $6
Jan-24-23Downgrade H.C. Wainwright Buy → Neutral $115 → $7
Jan-06-23Downgrade Wedbush Outperform → Neutral $42 → $7
Jan-06-23Downgrade Truist Buy → Hold $46 → $7
Jan-06-23Downgrade Stifel Buy → Hold $107 → $5.30
Jan-06-23Downgrade Piper Sandler Overweight → Neutral $71 → $12
Jan-06-23Downgrade Cowen Outperform → Market Perform
Jan-06-23Downgrade BofA Securities Buy → Underperform $72 → $4
Today 04:01PM
Dec-02-24 09:55AM
Nov-29-24 01:05PM
Nov-26-24 04:01PM
Nov-18-24 08:05AM
08:00AM Loading…
08:00AM
Nov-12-24 05:20PM
04:18PM
04:01PM
Nov-09-24 01:30PM
Nov-08-24 04:01PM
Nov-04-24 04:01PM
Oct-02-24 04:01PM
Sep-12-24 04:01PM
11:30AM
12:00PM Loading…
Aug-16-24 12:00PM
Aug-13-24 05:25PM
04:25PM
04:05PM
Aug-02-24 04:01PM
Jul-31-24 08:00AM
Jul-21-24 05:37AM
Jul-02-24 04:01PM
Jun-04-24 04:01PM
May-29-24 04:01PM
May-13-24 10:48AM
May-10-24 02:50PM
10:36AM
08:22AM
May-09-24 08:58PM
05:25PM Loading…
05:25PM
04:21PM
04:01PM
08:30AM
May-06-24 08:00AM
May-03-24 04:30PM
Apr-22-24 04:30PM
Apr-06-24 02:17AM
Apr-04-24 11:30PM
Apr-03-24 08:00AM
Apr-02-24 04:01PM
Mar-27-24 11:30AM
Mar-19-24 08:44AM
Mar-05-24 04:01PM
Mar-01-24 08:09AM
08:00AM
Feb-27-24 09:16AM
08:07AM
Feb-26-24 05:10PM
04:35PM
04:08PM
04:01PM
Feb-21-24 09:21AM
Feb-19-24 10:00AM
Feb-15-24 08:00AM
Feb-02-24 04:01PM
Jan-30-24 07:54AM
Jan-29-24 02:53PM
Jan-08-24 08:00AM
Dec-22-23 12:00PM
Dec-18-23 02:58PM
Dec-13-23 05:00PM
Dec-08-23 11:30AM
Nov-09-23 01:18PM
Nov-08-23 06:18PM
04:08PM
04:01PM
Oct-25-23 08:00AM
Sep-15-23 06:01AM
Sep-07-23 11:30AM
Aug-31-23 08:00AM
Aug-29-23 07:30AM
Aug-09-23 12:12PM
11:04AM
Aug-08-23 05:15PM
04:11PM
04:01PM
Jul-28-23 08:00AM
Jul-22-23 08:35AM
Jul-01-23 10:33AM
Jun-16-23 03:53PM
Jun-14-23 06:42AM
Jun-08-23 11:30AM
Jun-07-23 11:30AM
Jun-04-23 08:27AM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-25-23 10:49AM
May-08-23 06:05AM
May-04-23 11:59AM
11:22AM
May-03-23 05:15PM
04:11PM
04:01PM
12:00PM
Apr-27-23 10:03AM
Apr-26-23 10:02AM
Apr-24-23 08:00AM
Apr-12-23 07:20AM
Mar-30-23 11:30AM
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Xu YuanDirectorAug 06 '24Sale4.236332,6788,669Aug 07 04:01 PM
Xu YuanDirectorAug 06 '24Proposed Sale4.236332,678Aug 06 10:34 AM
Dulac Edward J IIIChief Financial OfficerMar 04 '24Sale7.772,44719,013101,479Mar 05 04:24 PM
Dulac Edward J IIIChief Financial OfficerJan 29 '24Sale5.001,8499,245103,926Jan 30 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryJan 09 '24Sale4.3710,87447,519142,361Jan 10 04:30 PM
Valamehr BahramChief R&D OfficerJan 09 '24Sale4.3811,27149,367158,069Jan 10 04:30 PM
Wolchko J ScottPresident and CEOJan 09 '24Sale4.3714,39162,889371,248Jan 10 04:29 PM
Dulac Edward J IIIChief Financial OfficerJan 09 '24Sale4.377,02830,712105,775Jan 10 04:29 PM
Dulac Edward J IIIChief Financial OfficerJan 02 '24Sale3.665,18218,966112,803Jan 03 04:03 PM
Redmile Group, LLCDirectorDec 26 '23Buy3.7244,630166,02413,180,388Dec 28 09:30 PM
Dulac Edward J IIIChief Financial OfficerDec 18 '23Sale3.501,5855,548117,985Dec 19 04:01 PM